Skip to main content
SpringerLink
Log in

Clinicopathological features, MIB-1 labeling index and apoptotic index in recurrent astrocytic tumors

  • Article
  • Published:
Pathology & Oncology Research

Abstract

This is a study of 64 cases of recurrent astrocytic tumors of all four WHO grades wherein a comparative evaluation of initial vs. recurrent tumor was done with respect to histological grading, MIB-1 labeling index (LI) and apoptotic index (AI). The aim was to identify factor/s that could influence interval to recurrence and/or malignant progression. Recurrence was noted in all grades and upon recurrence, 93.3% of grade II (low grade diffuse) astrocytomas and 63.6% of grade III anaplastic astrocytomas underwent malignant progression. However, none of the Grade I tumors showed evidence of malignant progression. Though interval to recurrence varied considerably, there was a correlation with histological grade of the initial tumor in that grade I and II tumors had a significantly longer mean interval to recurrence (43 months and 54.8 months respectively) as compared to grade III and IV (glioblastoma multiforme) tumors (17.6 and 12.8 months respectively). The interval to recurrence was also longer for grade II and III tumors which showed progression on recurrence (55.3 months for Grade II → Grade III; 54 months for Grade II → Grade IV and 20.6 months for Grade III → IV) as compared to tumors which recurred to the same grade (12.5 months for Grade III → Grade III and 12.8 months for Grade IV→ Grade IV). A statistically significant inverse correlation of MIB-1 LI with interval to recurrence was noted. Higher the MIB-1 LI, shorter was the interval to recurrence. Further a cut off MIB-1 LI value of 2.8% could be proposed in predicting recurrence free survival. Interestingly, MIB-1 LI of grade II tumors, which had progressed to grade IV was significantly higher than MIB-1 LI of grade II tumors which had progressed to grade III. Thus, this study establishes the potential role of MIB-1 LI of the initial tumor in determining interval to recurrence. However, apoptotic index has no role in predicting either interval to recurrence or malignant progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Afra D, Muller W: Recurrent low grade gliomas. Dedifferentiation and prospects of re-operation. In: Glioma. [Edt. Karim and Laws]. Springer Verlag, Berlin, Heidelberg. pp 189–203, 1991.

    Google Scholar 

  2. Afra D, Muller W, Benoist G, et al: Supratentorial recurrences of gliomas: Results of re-operation on astrocytomas and oligo-dendrogliomas. Acta Neurochir (Wien) 43:217–227, 1978.

    Article  CAS  Google Scholar 

  3. Carrol RS, Zhang J, Chauncey BW, et al: Apoptosis in astrocytic neoplasms. Acta Neurochir (Wien) 139:845–850, 1997.

    Article  Google Scholar 

  4. Ellison DW, Steart PV, Bateman AC, et al: Prognostic indicators in a range of astrocytic tumors: An immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neuro Surg Psychiatry 59:413–419, 1995.

    CAS  Google Scholar 

  5. Ellison DW, Steart PV, Gatter KC, et al: Apoptosis in cerebral astrocytic tumor and its relationship to expression of the Bcl-2 and p53 proteins. Neuropathol 21:352–361, 1995.

    Article  CAS  Google Scholar 

  6. Enestrom S, Vavruch L, Franlund B, et al: Ki-67 antigen expression as a prognostic factor in primary and recurrent astrocytomas. Neurochir 44:25–30, 1998.

    CAS  Google Scholar 

  7. Heesters MA, Koudstaal J, Go KG, et al: Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value. J Neurooncol 44:255–266, 1999.

    Article  PubMed  CAS  Google Scholar 

  8. Hilton DA, Love S, Barber R, et al: Accumulation of p53 and Ki67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy. Neurosurgery 42:724–729, 1998.

    Article  PubMed  CAS  Google Scholar 

  9. Hoshi M, Yoshida K, Shimazaki K: Correlation between MIB-1 staining indices and recurrence in low grade astrocytomas. Brain Tumor Pathol. 14:47–51, 1997.

    Article  PubMed  CAS  Google Scholar 

  10. Hoshino T, Ahn D, Prados MD, et al: Prognostic significance of the proliferative potential of intracranial gliomas measured by Bromodeoxyuridine labeling. Int J Cancer 53:550–555, 1993.

    Article  PubMed  CAS  Google Scholar 

  11. Hoshino T, Rodriguez LA, Cho KG, et al: Prognostic implications of the proliferative potential of low grade astrocytomas. J Neuro Surg 69:839–842, 1988.

    CAS  Google Scholar 

  12. Ito S, Chandler KL, Prados MD, et al: Proliferative potential and prognostic evaluation of low grade astrocytomas. J Neuro Oncol 19:1–9, 1994.

    Article  CAS  Google Scholar 

  13. Iuzzolino PO, Ghimenton C, Nicolato A, et al: p53 in low grade astrocytomas: a study with long-term follow-up. Br J Cancer 69:586–591, 1994.

    PubMed  CAS  Google Scholar 

  14. Jaros E, Perry RH, Adam L, et al: Prognostic implication of p53 protein, EGFR and Ki67 labeling in brain tumors. Br J Cancer 66:373–380, 1992.

    PubMed  CAS  Google Scholar 

  15. Kaluza J, Adamek D, Pyrich M: Ki-67 as a marker of proliferation activity in tumor progression of recurrent gliomas of supratentorial localization. Immunocytochemical quantitative studies. Pol J Pathol 48:31–36, 1997.

    PubMed  CAS  Google Scholar 

  16. Cavenee WK, Bigner DD, Newcomb EW, et al: Diffuse astrocytomas. In: Pathology and genetics tumors of the nervous system. (Eds. Kleihues P and Cavenee WK). International Agency for Research on Cancer, Lyon, 1997, pp 2–9.

    Google Scholar 

  17. Krans JA, Bolln C, Wolf HK, et al: TP53 alterations and clinical outcome in low grade astrocytoma. Genes Chromosomes 10:143–149, 1994.

    Article  Google Scholar 

  18. Laws ER Jr, Taylor WG, Clinjton MB, et al: Neurosurgical management of low grade astrocytoma of the cerebral hemispheres. J Neurosug 61:665–73, 1984.

    Article  Google Scholar 

  19. Litofsky NS, Mix TC, Baker SP, et al: Ki-67 proliferation index in recurrent glial neoplasms: no prognostic significance. Surg Neurol 50:579–585, 1998.

    Article  PubMed  CAS  Google Scholar 

  20. McKeever PE, Strawderman MS, Yamini B, et al: MIB-1 proliferation index predicts survival among patients with grade II astrocytoma. J Neuropathol Exp Neurol 57:931–936, 1998.

    Article  PubMed  CAS  Google Scholar 

  21. Montine TJ, Vandersteenhoven JJ, Aguzzi A, et al: Prognostic significance of Ki 67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery 34:674–678, 1994.

    Article  PubMed  CAS  Google Scholar 

  22. Muller W, Afra D, Schroeder R: Supratentorial recurrences of gliomas. Morphological studies in relation to time intervals with astrocytomas. Acta Neurochir 37:75–91, 1977.

    Article  CAS  Google Scholar 

  23. Mustonen M, Rainio H, Paakko P, et al: The extent of apoptosis is inversely associated with bcl-2 expression in pre-malignant and malignant breast lesions. Histopathology 31:347–354, 1997.

    Article  PubMed  CAS  Google Scholar 

  24. Nakamura M, Konishi N, Tsunoda S, et al: Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytomas. Cancer 80:242–249, 1997.

    Article  PubMed  CAS  Google Scholar 

  25. Rasheed BKA, McLendon RK, Herndon JD, et al: Alterations of the TP53 gene in human gliomas. Cancer Res 54:1324–1330, 1994.

    PubMed  CAS  Google Scholar 

  26. Recht LD, Law R, Smith TW: Suspected low grade glioima: Is deferring treatment safe? Ann Neurol 31:431–436, 1992.

    Article  PubMed  CAS  Google Scholar 

  27. Rieger J, Ohgaki H, Kleihues P, et al: Human astrocytic brain tumors express Apo2L/Trail. Acta Neuropathol (Berl) 97:1–4, 1999.

    Article  CAS  Google Scholar 

  28. Reifenberger J, Ring GU, Gies U, et al: Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 55:822–831, 1996.

    Article  PubMed  CAS  Google Scholar 

  29. Schiffer D, Chio A, Giordano MT, et al: Prognostic value of histologic features in adult cerebral astrocytomas. Cancer 61:1386–1393, 1988.

    Article  PubMed  CAS  Google Scholar 

  30. Soffietti R, Chio A, Giordano MT, et al: Prognostic factors in well differentiated cerebral astrocytomas in the adult. Neurosurgery 24:686–692, 1989.

    Article  PubMed  CAS  Google Scholar 

  31. Tandon PN, Mahapatra AK, Sarkar C, et al: Recurrence of supratentorial gliomas. Neurol India 45:141–149, 1997.

    Google Scholar 

  32. Vertosik FT, Selker RG, Arena VC: Survival of patients with well differentiated astrocytomas diagnosed in the era of computed tomography. Neurosurgery 28:496–501, 1991.

    Article  Google Scholar 

  33. von Deimling A, Eibl RH, Ohgaki H, et al: p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytomas. Cancer Res 52:2987–2990, 1992.

    Google Scholar 

  34. von Deimling A, Louis DN, Menon AG, et al: Allelicloss on the long arm of chromosome 17 in pilocytic astrocytoma. Acta Neuropathol 76:81, 1993.

    Article  Google Scholar 

  35. Watanabe K, Peraud A, Gratas C, et al: p53 and PTEN mutations in gennistocytic astrocytomas. Acta Neuropathol (Berl) 95:559–560, 1998.

    Article  CAS  Google Scholar 

  36. Watanabe K, Tachibana O, Yonekawa, et al: Role of gemistocytes in astrocytoma progression. Lab Invest 76:277–284, 1997.

    PubMed  CAS  Google Scholar 

  37. Winger MJ, Macdonald DR, Cairncross JG: Supratentorial anaplastic gliomas in adults. The prognostic important of extent of resection and prior low grade glioma. J Neurosurg 71:787–793, 1989.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, All India Institute of Medical Sciences, 110029, New Delhi, India

    Angela Mercy Ralte, Mehar Chand Sharma, Asis Kumar Karak, Veer Singh Mehta & Chitra Sarkar

  2. Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi

    Veer Singh Mehta

Authors
  1. Angela Mercy Ralte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mehar Chand Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Asis Kumar Karak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Veer Singh Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chitra Sarkar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chitra Sarkar.

Additional information

Supported by Indian Council of Medical Research

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ralte, A.M., Sharma, M.C., Karak, A.K. et al. Clinicopathological features, MIB-1 labeling index and apoptotic index in recurrent astrocytic tumors. Pathol. Oncol. Res. 7, 267–278 (2001). https://doi.org/10.1007/BF03032383

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03032383

Keywords

Search

Navigation